The combination of Mylan with Pfizer 's (NYSE: PFE) Upjohn unit to create Viatris (NASDAQ: VTRS) was supposed to create a cash-generating generic-drug company with the potential for future growth. Unfortunately the initial results for the combined company have been disappointing. In this video from Motley Fool Live , recorded on Mar . 1 , Fool.com Contributors Brian Orelli and Keith Speights discuss Viatris' recent revenue guidance and what to look for going forward.
For further details see:
Should Pfizer's and Mylan's Shareholders Sell Their Shares of Viatris?